Imaging Reveals Response to Targeted Glioma Treatment (image)

Caption
Three-dimensional magnetic resonance spectroscopy imaging reveals a decrease in tumor levels of 2-hydroxyglurate -- a metabolite that may contribute to tumor initiation -- in a patient with IDH1-mutated glioma after a week of treatment with an investigational targeted drug.
Credit
Ovidiu Andronesi, M.D., Ph.D., Martinos Center for Biomedical Imaging, Massachusetts General Hospital
Usage Restrictions
Usage restricted to coverage of the study described in this release.